drugset / Trial / NCT01480388
A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to assess the efficacy, safety and tolerability of JNJ-39758979 at doses of 10, 30, 100, and 300 mg/day compared with placebo (inactive medical substance) in patients with active rheumatoid arthritis despite concomitant treatment with methotrexate (MTX).
Timeline
- Start
- 2011-12
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-39758979 | Small molecule | 10 mg | Oral |
| Subject | JNJ-39758979 | Small molecule | 30 mg | Oral |
| Subject | JNJ-39758979 | Small molecule | 100 mg | Oral |
| Subject | JNJ-39758979 | Small molecule | 300 mg | Oral |